<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Examination of the clinical utility of SN38 (10-hydroxy-7-ethyl-<z:chebi fb="0" ids="27656">camptothecin</z:chebi>), the active metabolite of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11, has not been possible to date due to poor solubility of SN38 </plain></SENT>
<SENT sid="1" pm="."><plain>Here we evaluated the activity of EZN-2208, a water-soluble <z:chebi fb="1" ids="46793">polyethyleneglycol</z:chebi>-SN38 conjugate, in pre-clinical models of Burkitt's non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) (Raji and Daudi), and follicular NHL (DoHH2) </plain></SENT>
<SENT sid="2" pm="."><plain>In vitro, the IC50 of EZN-2208 ranged from 3-24 nM, which was 30- to 45-fold lower than <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 or 2.5- to 3.5-fold higher than SN38 </plain></SENT>
<SENT sid="3" pm="."><plain>In both an early-disease Raji model and an advanced-disease Daudi model, treatment with multiple doses of EZN-2208 resulted in 90% and 100% cures of animals, respectively (cure defined as no sign of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> by gross observations at the termination of study) </plain></SENT>
<SENT sid="4" pm="."><plain>The activity of EZN-2208 was dramatically superior to that of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 in <z:hpo ids='HP_0000001'>all</z:hpo> three models </plain></SENT>
<SENT sid="5" pm="."><plain>The excellent therapeutic efficacy of EZN-2208 in several B-cell NHL <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> merits its evaluation in the clinic for lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>